Polianta Ltd Makes New Investment in CVS Health Corporation $CVS

Key Points

• Polianta Ltd acquired 20,500 shares of CVS Health, valued at approximately $1.41 million, as part of their second-quarter investments.
• CVS Health's stock currently has a consensus target price of $77.89, with a rating of "Moderate Buy" from analysts, who have varied opinions ranging from "hold" to "strong-buy."
• The company declared a quarterly dividend of $0.665 per share, representing an annualized dividend yield of 3.6% and highlighting a payout ratio of 74.30%.

Polianta Ltd bought a new position in CVS Health Corporation (NYSE:CVS - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,500 shares of the pharmacy operator's stock, valued at approximately $1,414,000. CVS Health accounts for approximately 0.6% of Polianta Ltd's holdings, making the stock its 27th largest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in CVS. Bell Investment Advisors Inc boosted its stake in shares of CVS Health by 119.8% in the 1st quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock valued at $31,000 after purchasing an additional 248 shares during the last quarter. McIlrath & Eck LLC increased its holdings in CVS Health by 32.6% during the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares in the last quarter. Roxbury Financial LLC raised its stake in shares of CVS Health by 78.3% in the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 202 shares during the period. Saudi Central Bank purchased a new position in CVS Health in the 1st quarter worth approximately $34,000. Finally, Livelsberger Financial Advisory purchased a new position in shares of CVS Health during the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 80.66% of the company's stock.

Insider Activity at CVS Health

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director owned 22,156 shares of the company's stock, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.22% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

CVS has been the topic of several recent analyst reports. Bernstein Bank cut their target price on CVS Health from $78.00 to $72.00 and set a "market perform" rating on the stock in a research note on Wednesday, July 16th. UBS Group raised shares of CVS Health from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $67.00 to $79.00 in a research note on Monday, August 18th. Robert W. Baird upgraded shares of CVS Health from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $71.00 to $82.00 in a report on Thursday, August 14th. Cowen restated a "buy" rating on shares of CVS Health in a research note on Monday, August 4th. Finally, Sanford C. Bernstein boosted their price objective on CVS Health from $72.00 to $77.00 and gave the company a "market perform" rating in a research report on Friday, September 5th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, CVS Health currently has a consensus rating of "Moderate Buy" and an average price target of $77.89.

CVS Health Price Performance

NYSE:CVS traded up $0.53 during trading hours on Friday, reaching $74.95. The company had a trading volume of 13,414,318 shares, compared to its average volume of 6,679,727. The stock has a 50-day moving average of $67.91 and a two-hundred day moving average of $66.63. The firm has a market capitalization of $95.06 billion, a PE ratio of 20.94, a PEG ratio of 0.83 and a beta of 0.62. CVS Health Corporation has a one year low of $43.56 and a one year high of $76.24. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The company had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The company's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health's payout ratio is presently 74.30%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.